Skip to content

Easier Xifaxan generics negative for Valeant: Wells Fargo

March 17, 2017

Wells Fargo analyst David Maris noted that Xifaxan generics just got a lot easier, which he views as a “significant negative” for Valeant Pharmaceuticals (NYSE: VRX).

Maris commented, “The FDA has posted new guidance today (3/17) on what is needed for generic Xifaxan, and we believe this is a game changing development that makes it much easier for generics to show bioequivalence (BE). Our current assumption of generic entry on Xifaxan is 2023, and while we are making no changes at this time, this makes us think the likelihood of generics entering then or earlier has just increased dramatically. We believe this is a new significant negative for Valeant.”

The analyst reiterated his Underperform rating.


From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: